Clinical trials: Leukemia/Lymphoma
Chronic Lymphocytic Leukemia, Small-Cell Lymphoma
A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
The primary objective of this study is to evaluate the efficacy of ibrutinib in combination with obinutuzumab compared to chlorambucil in combination with obinutuzumab based on the Independent Review Committee (IRC) assessment of…
- Trial name
- NCT02264574
- Testing
- Ibrutinib, Obinutuzumab, Chlorambucil
- Where
- 71 sites in United States, Australia and 14 more
- Volunteers
- 229 people
- Sponsor
- Pharmacyclics LLC.
Leukemia, Lymphocytic, Chronic, B-Cell
A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies
The purpose of this study is to compare the efficacy and safety of liso-cel vs Investigator's Choice options (idelalisib + rituximab or bendamustine + rituximab) in adult participants with R/R CLL or SLL, whose disease has failed…
- Trial name
- NCT06205290
- Testing
- Liso-cel, Idelalisib, Rituximab
- Where
- 48 sites in United States, Austria and 9 more
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Lymphoma, Breast Neoplasms
Chemotherapy Related Anemia in Patients With Non-Myeloid Malignancies
Chemotherapy can often cause anemia in patients with cancer. Anemia is a low number of red blood cells. The symptoms of anemia may include fatigue, dizziness, headache, chest pain, and shortness of breath.
- Conditions
- Lymphoma, Breast Neoplasms, Lung Neoplasms, Multiple Myeloma
- Trial name
- NCT00036023
- Testing
- darbepoetin alfa
- Sponsor
- Amgen
Acute Myeloid Leukaemia (AML), Follicular Lymphoma ( FL)
A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
The TEMPUS AQUARIUS Study is a non-interventional, longitudinal observational study focused on hematological malignancies. It will collect rich molecular (multi-omic) and clinical data from patient cohorts through serial blood…
- Trial name
- Aquarius (NCT07154823)
- Testing
- None - Observational Study
- Where
- 13 sites in United States
- Volunteers
- 550 people
- Sponsor
- Tempus AI
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)
The purpose of this study is to evaluate the safety, pharmacokinetics, immunogenicity, and efficacy of zilovertamab vedotin given intravenously (IV) across a range of dose levels in participants with previously treated…
- Conditions
- Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma
- Trial name
- NCT03833180
- Testing
- Zilovertamab vedotin
- Where
- 14 sites in United States
- Volunteers
- 91 people
- Sponsor
- VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Relapsed or Refractory Haematological Malignancies Including, Acute Myeloid Leukemia
Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies
The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary antitumor activity of AZD4573 in subjects with relapsed or refractory haematological malignancies.
- Conditions
- Relapsed or Refractory Haematological Malignancies Including, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia
- Trial name
- NCT03263637
- Testing
- AZD4573
- Where
- 12 sites in Germany, Netherlands and 1 more
- Volunteers
- 44 people
- Sponsor
- AstraZeneca
B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma
Efficacy and Safety of PZ01 Treatment in Patients With r/r CD19+ B-cell Acute Lymphoblastic Leukemia/B Cell Lymphoma
The major aim of this research is to assess the feasibility, safety and effectiveness of CD19 CAR-T Cell Therapy for Relapsed/ Refractory Acute Lymphoblastic Leukemia/ B cell Lymphoma patients who have applied it.
- Trial name
- NCT03281551
- Testing
- PZ01 CAR-T cells
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Pinze Lifetechnology Co. Ltd.
Leukemia, Lymphoma
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy
Ex vivo expanded human myeloid progenitor cells (hMPCs; CLT-008) have the potential to accelerate neutrophil recovery in patients receiving myeloablative conditioning as part of an umbilical cord blood transplant for hematologic…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma, Plasma Cell Neoplasm
- Trial name
- NCT00891137
- Testing
- human myeloid progenitor cells
- Where
- 8 sites in United States
- Volunteers
- 30 people
- Sponsor
- Cellerant Therapeutics
Acute Lymphoblastic Leukemia, Non Hodgkin Lymphoma
Safety and Efficacy Evaluation of Next-generation CD19-UCART
The purpose of this study is to evaluate the safety and efficacy of Next-generation CD19-UCART in patients with relapsed or refractory B-cell hematological malignancies.
- Trial name
- NCT05381181
- Testing
- CD19-UCART
- Volunteers
- 20 people
- Sponsor
- Bioray Laboratories
Graft Versus Host Disease, Leukemia
OTI-010 for Graft-Versus-Host Disease Prophylaxis in Treating Patients Who Are Undergoing Donor Peripheral Stem Cell Transplantation for Hematologic Malignancies
RATIONALE: OTI-010 may be effective for graft-versus-host disease prophylaxis (prevention) in patients who are undergoing donor peripheral stem cell transplantation for hematologic malignancies (cancer of the blood or bone…
- Conditions
- Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT00081055
- Testing
- autologous expanded mesenchymal stem cells OTI-010, busulfan, cyclophosphamide
- Where
- United States
- Sponsor
- Mesoblast International Sàrl
Adult T-Cell Lymphoma (ATL)
Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Adult T Cell Lymphoma (ATL)
Phase 2b, open-label, non-randomized, single arm study to evaluate the safety, and efficacy of HBI-8000 40 mg BIW in patients with relapsed or refractory ATL (R/R ATL)
- Trial name
- NCT02955589
- Testing
- HBI-8000
- Where
- 15 sites in Japan
- Volunteers
- 23 people
- Sponsor
- HUYABIO International, LLC.
CLL / SLL, CLL (Chronic Lymphocytic Leukemia)
A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies
This Phase 1, open-label, multicenter study is evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of lonitoclax (ZE50-0134) in adults with relapsed or refractory chronic…
- Conditions
- CLL / SLL, CLL (Chronic Lymphocytic Leukemia), SLL (Small Lymphocytic Lymphoma), Marginal Zone Lymphoma(MZL)
- Trial name
- NCT06708897
- Testing
- Lonitoclax (ZE50-0134)
- Where
- 5 sites in United States
- Volunteers
- 84 people
- Sponsor
- Lomond Therapeutics Holdings, Inc.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Study of Dinaciclib in Combination With Rituximab in Participants With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (P07974)
The purpose of this study is to determine the maximum-tolerated dose (MTD) of dinaciclib therapy in combination with rituximab in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
- Trial name
- NCT01650727
- Testing
- Dinaciclib, Rituximab
- Volunteers
- 5 people
- Sponsor
- Merck Sharp & Dohme LLC
Solid Tumors, Leukemia, Lymphocytic, Acute, Pediatric
Clofarabine in Adult Patients With Advanced Solid Tumors
Clofarabine (injection) is approved by the Food and Drug Administration (FDA) for the treatment of pediatric patients 1 to 21 years old with relapsed acute lymphoblastic leukemia (ALL) who have had at least 2 prior treatment…
- Conditions
- Solid Tumors, Leukemia, Lymphocytic, Acute, Pediatric, Leukemia, Lymphocytic, Acute, Adult, Leukemia, Myelocytic, Acute, Pediatric
- Trial name
- NCT00125840
- Testing
- clofarabine (IV formulation)
- Where
- 2 sites in United States
- Sponsor
- Genzyme, a Sanofi Company
Acute Leukemia
A Study for Patients With Acute Leukemia
This study is a multicenter, nonrandomized, open-label, dose-escalation with intra-patient dose-escalation, Phase 1 study of intravenous LY2523355 to determine the dose of LY2523355 that can be safely administered to participants…
- Trial name
- NCT01214655
- Testing
- LY2523355
- Where
- 5 sites in United States
- Volunteers
- 33 people
- Sponsor
- Eli Lilly and Company
Myelofibrosis, Acute Lymphocytic Leukemia (ALL)
Expanded Access to Navitoclax
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to navitoclax prior to approval by the local regulatory agency. Availability will depend on territory eligibility.
- Conditions
- Myelofibrosis, Acute Lymphocytic Leukemia (ALL), Lymphoblastic Lymphoma
- Trial name
- NCT03592576
- Testing
- Navitoclax, Venetoclax
- Sponsor
- AbbVie
Anemia
A Study to Assess the Hematopoyetic Response of Anemic Patients With Hematologic Malignancies Treated With Erythropoietin B
This study will examine the efficacy, safety and effect on hemoglobin levels, of once weekly subcutaneous injections of epoetin beta (30,000 IU) in anemic participants with non-Hodgkin's lymphoma, chronic lymphocytic leukemia or…
- Trial name
- NCT02608060
- Testing
- Epoetin Beta
- Where
- 2 sites in Venezuela
- Volunteers
- 4 people
- Sponsor
- Hoffmann-La Roche
Pediatric ALL
Investigation of Remimazolam in Children Undergoing Sedation for Medical Procedures
To assess the efficacy of intravenous remimazolam in inducing and maintaining suitable sedation levels for paediatric patients undergoing diagnostic and/or therapeutic procedures
- Trial name
- NCT04851717
- Testing
- Remimazolam
- Where
- 8 sites in United States, Denmark
- Volunteers
- 100 people
- Sponsor
- Acacia Pharma Ltd
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
The purpose of this study is to examine the safety and efficacy of Ibrutinib administered in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small…
- Trial name
- NCT01611090
- Testing
- Ibrutinib, Bendamustine hydrochloride, Rituximab
- Where
- 155 sites in United States, Argentina and 19 more
- Volunteers
- 578 people
- Sponsor
- Janssen Research & Development, LLC
B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies
This is Phase 1b/2 study to investigate the safety and effectiveness of the investigational drug, cirmtuzumab, when given in combination with ibrutinib in patients with B-cell lymphoid malignancies.
- Conditions
- B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma
- Trial name
- NCT03088878
- Testing
- Cirmtuzumab (2-16 kg/mg) plus Ibrutinib, Cirmtuzumab (300mg) plus Ibrutinib, Cirmtuzumab (600 mg) plus ibrutinib
- Where
- 12 sites in United States
- Volunteers
- 95 people
- Sponsor
- Oncternal Therapeutics, Inc